|
US6184201B1
(en)
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
|
US5834428A
(en)
*
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
|
EP2275438A1
(en)
|
1996-04-12 |
2011-01-19 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
|
US20020025933A1
(en)
*
|
1996-08-30 |
2002-02-28 |
Knudsen Liselotte Bjerre |
GLP-2 derivatives
|
|
CA2236519C
(en)
*
|
1997-05-02 |
2011-09-13 |
1149336 Ontario Inc. |
Methods of enhancing functioning of the large intestine
|
|
SE9802080D0
(sv)
*
|
1998-06-11 |
1998-06-11 |
Hellstroem |
Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
|
|
EP1137667B1
(en)
|
1998-12-07 |
2004-11-17 |
Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. |
Analogues of glp-1
|
|
GB9930882D0
(en)
*
|
1999-12-30 |
2000-02-23 |
Nps Allelix Corp |
GLP-2 formulations
|
|
US20070135345A1
(en)
*
|
2000-09-18 |
2007-06-14 |
Henriksen Dennis B |
Use of GLP-2 for the treatment or prevention, of bone-related disorders
|
|
US7371721B2
(en)
*
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
US20080249016A1
(en)
*
|
2000-09-18 |
2008-10-09 |
Sanos Bioscience A/S |
Use of GLP-2 in a combination treatment for bone-related disorders
|
|
PT1326630E
(pt)
|
2000-09-18 |
2008-09-02 |
Sanos Bioscience As |
Utilização de péptidos glp-2
|
|
DK1360202T3
(da)
*
|
2001-02-16 |
2008-09-22 |
Conjuchem Biotechnologies Inc |
Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
|
|
US7411039B2
(en)
*
|
2002-10-14 |
2008-08-12 |
Novo Nordisk A/S |
GLP-2 compounds, formulations, and uses thereof
|
|
DE602004031927D1
(de)
|
2003-02-04 |
2011-05-05 |
Novo Nordisk As |
Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
|
|
EP1608680A2
(en)
*
|
2003-03-24 |
2005-12-28 |
Novo Nordisk A/S |
Glp-2 derivatives
|
|
EP1633384B1
(en)
|
2003-05-15 |
2012-03-14 |
Trustees Of Tufts College |
Stable analogs of glp-1
|
|
EP1711523B1
(en)
|
2003-12-16 |
2012-10-10 |
Ipsen Pharma |
Analogues of glp-1
|
|
EP2033662B1
(en)
|
2004-01-21 |
2012-10-17 |
Novo Nordisk Health Care AG |
Transglutaminase mediated conjugation of peptides
|
|
DK1809318T3
(da)
|
2004-11-01 |
2013-09-08 |
Nps Pharma Inc |
Behandling af korttarmssyndrom-patienter med tyktarmskontinuitet
|
|
DE602006020123D1
(de)
|
2005-05-04 |
2011-03-31 |
Zealand Pharma As |
Glucagon-like-peptide-2- (glp-2-) analoga
|
|
WO2007119101A2
(en)
|
2005-12-01 |
2007-10-25 |
Nps Allelix Corp. |
Assay system for glp-2 receptor ligands
|
|
AU2007319066B2
(en)
*
|
2006-11-08 |
2013-09-19 |
Zealand Pharma A/S |
Selective glucagon-like-peptide-2 (GLP-2) analogues
|
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
|
EP2627770B1
(en)
|
2010-10-15 |
2017-06-28 |
Cornell University |
Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
|
|
CN102924589B
(zh)
*
|
2011-08-11 |
2016-08-24 |
中肽生化有限公司 |
胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
|
|
ES2687651T3
(es)
|
2011-09-12 |
2018-10-26 |
Amunix Operating Inc. |
Composiciones de péptido-2 similar a glucagón y métodos para producir y usar los mismos
|
|
CN104302408B
(zh)
|
2012-02-27 |
2016-12-14 |
阿穆尼克斯运营公司 |
Xten缀合组合物和制造其的方法
|
|
EA028929B1
(ru)
|
2012-05-03 |
2018-01-31 |
Зилэнд Фарма А/С |
Аналоги глюкагоноподобного пептида-2 (glp-2)
|
|
KR102502040B1
(ko)
|
2016-12-09 |
2023-02-24 |
질랜드 파마 에이/에스 |
아실화 glp-1/glp-2 이중 효능제
|
|
IL271245B2
(en)
|
2017-06-16 |
2023-10-01 |
Zealand Pharma As |
Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
|
|
WO2020020904A1
(en)
|
2018-07-23 |
2020-01-30 |
Zealand Pharma A/S |
Therapeutic uses of glp-2 agonists
|